Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Sym015 shows superior specificity compared to TKIs for NSCLC

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
Sym015 shows superior specificity compared to TKIs for NSCLC ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )
29 May 2020

Brigatinib for NSCLC, latest research and overcoming complications

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
Brigatinib for NSCLC, latest research and overcoming complications ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )
29 May 2020

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

Prof Roy Herbst - Yale Cancer Center, New Haven, USA
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )
29 May 2020

Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )
27 May 2020

Do immune checkpoint inhibitors work in EGFR mutant lung cancer?

Dr Edward Garon - UCLA Medical Center, Santa Monica, USA
Do immune checkpoint inhibitors work in EGFR mutant lung cancer? ( Dr Edward Garon - UCLA Medical Center, Santa Monica, USA )
22 May 2020

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms

Dr Akhil Kapoor - Tata Memorial Center, Mumbai, India
Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms ( Dr Akhil Kapoor - Tata Memorial Center, Mumbai, India )
15 May 2020

IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutation-positive advanced melanoma

Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutation-positive advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia )
1 May 2020

Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma

Prof Alain Algazi -University of California San Francisco, San Francisco, USA
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma ( Prof Alain Algazi -University of California San Francisco, San Francisco, USA )
30 Apr 2020

New oncogenic drivers in NSCLC

Prof Egbert Smit - Netherlands Cancer Institute, Amsterdam, Netherlands
New oncogenic drivers in NSCLC ( Prof Egbert Smit - Netherlands Cancer Institute, Amsterdam, Netherlands )
23 Apr 2020

The potential of KRAS inhibitors for non-small-cell lung cancer

Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany
The potential of KRAS inhibitors for non-small-cell lung cancer ( Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany )
22 Apr 2020

Novel treatment strategies for prostate cancer: Senescence, senolytics and myeloid derived suppressor cells

Prof Andrea Alimonti - Institute of Oncology Research, Bellinzona, Switzerland
Novel treatment strategies for prostate cancer: Senescence, senolytics and myeloid derived suppressor cells ( Prof Andrea Alimonti - Institute of Oncology Research, Bellinzona, Switzerland )
9 Apr 2020

Immune checkpoint based approaches in AML and MDS

Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
Immune checkpoint based approaches in AML and MDS ( Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA )
8 Apr 2020